Douglas Elliman Inc. (NYSE:DOUG – Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 699,000 shares, an increase of 25.2% from the February 28th total of 558,400 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily volume of 743,600 shares, the short-interest ratio is presently 0.9 days.
Douglas Elliman Price Performance
NYSE DOUG traded down $0.02 on Wednesday, reaching $1.70. The company’s stock had a trading volume of 291,485 shares, compared to its average volume of 881,525. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.62 and a current ratio of 4.62. The firm’s 50 day moving average is $1.85 and its two-hundred day moving average is $1.87. Douglas Elliman has a twelve month low of $1.00 and a twelve month high of $2.98. The stock has a market cap of $150.41 million, a PE ratio of -1.65 and a beta of 1.56.
Douglas Elliman (NYSE:DOUG – Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.11. The company had revenue of $243.32 million during the quarter. Douglas Elliman had a negative net margin of 8.81% and a negative return on equity of 22.85%.
Institutional Trading of Douglas Elliman
Douglas Elliman Company Profile
Douglas Elliman Inc owns Douglas Elliman Realty, LLC, operating as a residential brokerage company in the United States with operations in New York, Florida, California, Texas, Colorado, Nevada, Massachusetts, Connecticut, Maryland, Virginia and Washington, DC In addition, Douglas Elliman sources, uses and invests in early-stage, disruptive property technology (“PropTech”) solutions and companies and provides other real estate services, including development marketing, property management and settlement and escrow services in select markets.
Featured Stories
- Five stocks we like better than Douglas Elliman
- How to Invest in Biotech Stocks
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- The 3 Most Talked About Investments on WallStreetBets Right Now
- How to Most Effectively Use the MarketBeat Earnings Screener
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Douglas Elliman Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Douglas Elliman and related companies with MarketBeat.com's FREE daily email newsletter.